Lipid Metabolism Practice Questions

Q: How does a defect in the enzyme 21-hydroxylase affect the synthesis of adrenal hormones?

Decreases aldosterone and cortisol synthesis. ***Decreases aldosterone and cortisol synthesis*** - 21-hydroxylase is a crucial enzyme in the adrenal steroid synthesis pathway, necessary for converting **progesterone** to **11-deoxycorticosterone** (a precursor to aldosterone) and **17-hydroxyprogesterone** to **11-deoxycortisol** (a precursor to cortisol). - A defect in this enzyme directly impairs the production of both **cortisol** and **aldosterone**, leading to their deficiency. - This is the hallmark of **congenital adrenal hyperplasia (CAH)** due to 21-hydroxylase deficiency. *Decreases cortisol production* - While cortisol production is decreased, this option is incomplete as it fails to mention the concurrent decrease in **aldosterone** synthesis, which is also a significant consequence of 21-hydroxylase deficiency. - The deficiency impacts multiple steroid pathways, not just the cortisol pathway in isolation. *Leads to decreased estrogen production* - Estrogen synthesis primarily occurs in the **gonads** and **peripheral tissues** from androgens, not directly regulated by 21-hydroxylase in the adrenal cortex. - A 21-hydroxylase defect leads to an **accumulation of androgen precursors** (like DHEA), which can be converted to estrogens peripherally, sometimes even increasing estrogen levels in certain forms of congenital adrenal hyperplasia. *Decreases androgen synthesis* - This is **incorrect** - a 21-hydroxylase defect causes a shunting of precursors towards the **androgen pathway**, leading to an **increase in androgen synthesis**, not a decrease. - This excess androgen production is responsible for the **virilization** observed in individuals with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, including ambiguous genitalia in females and precocious puberty in males.

Q: Which enzyme deficiency leads to the accumulation of ceramide trihexoside in Fabry disease?

α-galactosidase A deficiency. ***α-galactosidase A deficiency*** - **Fabry disease** is an **X-linked recessive** lysosomal storage disorder caused by a deficiency of the enzyme **α-galactosidase A**. - This enzyme deficiency leads to the accumulation of its substrate, **globotriaosylceramide (Gb3)**, also known as **ceramide trihexoside**, in various tissues. *β-glucosidase deficiency* - This deficiency is characteristic of **Gaucher disease**, leading to the accumulation of **glucocerebroside**. - Patients typically present with **hepatosplenomegaly**, **bone pain**, and **pancytopenia**, which are not features of Fabry disease. *Hexosaminidase A deficiency* - This enzyme deficiency is associated with **Tay-Sachs disease**, which results in the accumulation of **GM2 gangliosides**. - Tay-Sachs disease primarily affects the **nervous system**, causing neurodegeneration in infancy. *Sphingomyelinase deficiency* - This deficiency causes **Niemann-Pick disease**, leading to the accumulation of **sphingomyelin** in lysosomes. - Clinical features include **hepatosplenomegaly**, **neurodegeneration** (especially in Type A), and characteristic **foam cells**.

Q: Which of the following enzymes is inhibited by malonyl-CoA to prevent simultaneous fatty acid synthesis and degradation?

Carnitine palmitoyltransferase I. ***Carnitine palmitoyltransferase I*** - **Malonyl-CoA** inhibits **carnitine palmitoyltransferase I (CPT1)**, which is crucial for transporting fatty acyl-CoAs into the mitochondria for **beta-oxidation**. - This inhibition ensures that when fatty acid synthesis is active (producing malonyl-CoA), fatty acid degradation is simultaneously suppressed, preventing a futile cycle. *Acetyl-CoA carboxylase* - **Acetyl-CoA carboxylase (ACC)** is the enzyme responsible for synthesizing **malonyl-CoA** from acetyl-CoA, not inhibited by it. - ACC is the committed step in **fatty acid synthesis** and is subject to allosteric regulation by citrate (activator) and long-chain fatty acids (inhibitor). *HMG-CoA reductase* - **HMG-CoA reductase** is a key enzyme in the synthesis of **cholesterol**, not directly involved in the primary regulation of fatty acid synthesis and degradation by malonyl-CoA. - It is inhibited by cholesterol and statin drugs. *Fatty acid synthase* - **Fatty acid synthase** is a multi-enzyme complex responsible for the elongation of fatty acids using **malonyl-CoA** as a substrate. - It is activated, not inhibited, by malonyl-CoA, which serves as a building block for fatty acid chains.

Q: A patient with high levels of LDL and normal levels of HDL and triglycerides is likely suffering from which type of familial dyslipidemia?

Familial hypercholesterolemia. ***Familial hypercholesterolemia*** - This condition is characterized by significantly **elevated LDL-C levels** due to defects in the LDL receptor pathway, leading to impaired clearance of LDL from the blood. - **HDL and triglyceride levels typically remain normal**, which aligns perfectly with the patient's lipid profile. *Familial combined hyperlipidemia* - This disorder involves **elevated levels of both cholesterol (primarily LDL-C) and triglycerides**, often with low HDL-C levels. - The patient's **normal triglyceride levels** make this diagnosis less likely. *Dysbetalipoproteinemia* - This condition is characterized by increased levels of **chylomicron remnants** and **VLDL remnants (IDL)**, leading to elevated cholesterol and triglycerides. - It typically results in **elevated triglycerides and cholesterol**, which is not seen here as triglycerides are normal. *Familial hypertriglyceridemia* - This condition primarily involves **markedly elevated triglyceride levels**, often with normal or only slightly elevated cholesterol and characteristically low HDL-C levels. - The patient's **normal triglyceride levels** directly rule out this diagnosis.

Q: A patient with type II diabetes is prescribed a drug that enhances insulin sensitivity by activating AMP-activated protein kinase (AMPK). What is the primary effect of AMPK activation on lipid metabolism?

Inhibits fatty acid synthesis. ***Inhibits fatty acid synthesis*** - **AMPK activation** leads to the phosphorylation and **inactivation of acetyl-CoA carboxylase (ACC)**, a key enzyme in fatty acid synthesis. - By inhibiting ACC, AMPK reduces the production of **malonyl-CoA**, which is both a substrate for fatty acid synthesis and an inhibitor of CPT-1, an enzyme crucial for fatty acid oxidation. - This is the **primary and direct action** of AMPK on lipid metabolism. *Promotes fatty acid oxidation* - While AMPK activation does generally promote **fatty acid oxidation**, this is an **indirect effect** resulting from the inhibition of fatty acid synthesis. - The inhibition of ACC relieves the malonyl-CoA-mediated inhibition of CPT-1, allowing fatty acid oxidation to proceed. - This is a secondary consequence, not the primary effect. *Stimulates lipid synthesis* - AMPK is a metabolic sensor that is activated during low energy states, and its primary role is to **conserve ATP**. - Stimulating lipid synthesis would be an **anabolic process** that consumes ATP, which is contrary to the energy-conserving role of AMPK. *Increases fatty acid storage* - Increased fatty acid storage, often in the form of triglycerides, is generally associated with an **excess of energy intake** and an increase in lipid synthesis. - AMPK's actions, by inhibiting fatty acid synthesis and promoting oxidation, would tend to **decrease fatty acid storage**, not increase it.

Q: What is the primary cause of ketoacidosis in uncontrolled diabetes mellitus?

Fat metabolism producing ketone bodies. ***Fat metabolism producing ketone bodies*** - In uncontrolled diabetes, the body cannot use **glucose** for energy due to insulin deficiency or resistance, leading to excessive breakdown of **fats** (lipolysis) for energy. - Free fatty acids undergo **β-oxidation** in the liver, producing excess acetyl-CoA that enters the **ketogenesis pathway**. - This produces large amounts of **ketone bodies** (acetoacetate, β-hydroxybutyrate, and acetone), which are acidic and accumulate faster than peripheral tissues can utilize them. - The accumulation of these organic acids lowers blood pH, causing **metabolic ketoacidosis** - the hallmark of diabetic ketoacidosis (DKA). *High blood glucose levels* - While hyperglycemia is characteristic of uncontrolled diabetes, it is a **consequence** of the underlying metabolic derangement, not the direct cause of the acidosis. - Hyperglycemia contributes to osmotic diuresis, dehydration, and electrolyte imbalances, but the **acidosis component is specifically due to ketone accumulation**. *Excessive insulin production* - **Diabetic ketoacidosis (DKA)** is characterized by an **absolute or relative deficiency of insulin**, not excessive production. - High insulin levels would promote glucose uptake into cells and inhibit lipolysis, preventing fat breakdown and thus preventing ketone body formation. *Lack of glucagon* - Glucagon levels are typically **elevated** in uncontrolled diabetes, as the body perceives a state of cellular starvation despite high blood glucose. - **Glucagon promotes glycogenolysis, gluconeogenesis, and lipolysis**, contributing to both hyperglycemia and enhanced ketone body formation, not preventing it.

Q: A patient with hypercholesterolemia has low LDL receptor activity. Which gene mutation is most likely responsible?

LDLR. ***LDLR*** - Mutations in the **LDLR (low-density lipoprotein receptor) gene** directly lead to reduced or dysfunctional LDL receptors, preventing efficient clearance of LDL from the blood. - This is the **most common genetic cause** of **Familial Hypercholesterolemia (FH)**, accounting for **~85-90% of cases**, characterized by very high LDL-C levels and premature cardiovascular disease. - **Most likely answer** when low LDL receptor activity is described. *APOB* - Mutations in the **APOB gene (apolipoprotein B)** can affect the binding of LDL to its receptor through **defective apolipoprotein B-100**, which is the ligand for the LDL receptor. - This causes a rare form of FH (~5-10% of cases) but represents a **ligand defect** rather than a primary **receptor defect**. - The receptor itself has normal structure but cannot bind LDL effectively. *PCSK9* - **PCSK9 (proprotein convertase subtilisin/kexin type 9)** regulates LDL receptor degradation, and **gain-of-function mutations** lead to **increased degradation of LDL receptors**, resulting in **reduced LDL receptor numbers and activity** on cell surfaces. - This does cause hypercholesterolemia and low functional LDL receptor activity, but accounts for only **~1-3% of FH cases**, making it **much less likely** than LDLR mutations. - Loss-of-function PCSK9 mutations conversely lead to **increased LDL receptors** and lower LDL levels (protective). *APOE* - **APOE (apolipoprotein E)** plays a crucial role in the metabolism of **chylomicron and VLDL remnants**, primarily binding to hepatic receptors for remnant clearance. - While APOE polymorphisms (E2, E3, E4) influence lipid levels and cardiovascular risk, they do not directly cause **reduced LDL receptor activity** or classic familial hypercholesterolemia. - APOE2 homozygosity can cause **Type III hyperlipoproteinemia** (dysbetalipoproteinemia), not the LDL receptor defect described.

Q: Which enzyme is responsible for converting dihydroxyacetone phosphate to glycerol-3-phosphate during triglyceride synthesis?

Glycerol-3-phosphate dehydrogenase. ***Glycerol-3-phosphate dehydrogenase*** - This enzyme **catalyzes the reduction** of **dihydroxyacetone phosphate (DHAP)**, a glycolysis intermediate, to **glycerol-3-phosphate**. - **NADH** serves as the **reducing agent** in this reaction, converting DHAP to glycerol-3-phosphate, which is the backbone for triglyceride synthesis. *Glycerol kinase* - This enzyme catalyzes the phosphorylation of **free glycerol** to **glycerol-3-phosphate**, using **ATP**. - It is primarily active in the **liver** and kidney, as adipocytes lack this enzyme, meaning they cannot directly use free glycerol for triglyceride synthesis. *Acyl-CoA synthetase* - This enzyme is responsible for **activating fatty acids** by converting them into **acyl-CoA**, using **ATP** and **CoA**. - This activation step is essential before fatty acids can be incorporated into triglycerides or phospholipids. *Phosphatidate phosphatase* - This enzyme **removes a phosphate group** from **phosphatidic acid** to form **diacylglycerol (DAG)**. - DAG is then acylated to form triglycerides, making this enzyme crucial in the final steps of triglyceride synthesis.

Q: What is the role of lecithin-cholesterol acyltransferase (LCAT) in lipid metabolism?

Converts free cholesterol into cholesteryl esters. ***Converts free cholesterol into cholesteryl esters*** - **LCAT** is an enzyme synthesized in the liver and secreted into the bloodstream, where it associates with **HDL** particles. - Its primary role is to catalyze the esterification of **free cholesterol** in the surface of lipoproteins, especially HDL, into **cholesteryl esters** using a fatty acid from lecithin. This traps cholesterol within the lipoprotein core, facilitating cholesterol transport. *Hydrolyzes triglycerides in lipoproteins* - The hydrolysis of triglycerides in lipoproteins, particularly **chylomicrons** and **VLDLs**, is primarily carried out by **lipoprotein lipase (LPL)**, an enzyme found on the endothelial surface of capillaries. - **Hepatic lipase (HL)** also contributes to triglyceride hydrolysis, especially in remnants and HDL, but LCAT's role is specifically cholesterol esterification. *Synthesizes triglycerides in the liver* - The synthesis of triglycerides in the liver, a process known as **lipogenesis**, involves enzymes such as **glycerol-3-phosphate acyltransferase** and **diacylglycerol acyltransferase (DGAT)**. - These enzymes are involved in assembling fatty acids and glycerol-3-phosphate into triglycerides, which are then packaged into **VLDL** particles for transport. *Breaks down cholesterol into bile acids* - The breakdown of cholesterol into **bile acids** (bile acid synthesis) occurs in the liver and is a major pathway for cholesterol elimination. - The rate-limiting enzyme in this process is **cholesterol 7-alpha-hydroxylase**, which initiates the conversion of cholesterol into primary bile acids.

Q: Which metabolic disorder is characterized by the accumulation of sphingomyelin in lysosomes?

Niemann-Pick disease. ***Niemann-Pick disease*** - This lysosomal storage disorder is specifically characterized by the accumulation of **sphingomyelin** due to a deficiency in the enzyme **sphingomyelinase**. - Clinical manifestations include **hepatosplenomegaly**, neurodegeneration, and a **cherry-red spot** on the retina in some types. *Tay-Sachs disease* - This disorder involves the accumulation of **GM2 gangliosides** in lysosomes due to a deficiency of **hexosaminidase A**. - It primarily affects the central nervous system, leading to **progressive neurodegeneration** and a cherry-red spot in the macula. *Gaucher disease* - Characterized by the buildup of **glucocerebroside** in lysosomes, caused by a deficiency in the enzyme **glucocerebrosidase**. - Key features include **hepatosplenomegaly**, bone pain, and neurologic manifestations in severe forms. *Fabry disease* - This X-linked disorder results from a deficiency of **alpha-galactosidase A**, leading to the accumulation of **globotriaosylceramide (Gb3)**. - Clinical signs include **acroparesthesias**, angiokeratomas, renal failure, and cardiac involvement.

Question 1

How does a defect in the enzyme 21-hydroxylase affect the synthesis of adrenal hormones?

Accepted Answer

Decreases aldosterone and cortisol synthesis

Answer

Decreases androgen synthesis

Answer

Decreases cortisol production

Answer

Leads to decreased estrogen production

Question 2

Which enzyme deficiency leads to the accumulation of ceramide trihexoside in Fabry disease?

Accepted Answer

α-galactosidase A deficiency

Answer

β-glucosidase deficiency

Answer

Hexosaminidase A deficiency

Answer

Sphingomyelinase deficiency

Question 3

Which of the following enzymes is inhibited by malonyl-CoA to prevent simultaneous fatty acid synthesis and degradation?

Accepted Answer

Carnitine palmitoyltransferase I

Answer

Acetyl-CoA carboxylase

Answer

HMG-CoA reductase

Answer

Fatty acid synthase

Question 4

A patient with high levels of LDL and normal levels of HDL and triglycerides is likely suffering from which type of familial dyslipidemia?

Accepted Answer

Familial hypercholesterolemia

Answer

Familial combined hyperlipidemia

Answer

Dysbetalipoproteinemia

Answer

Familial hypertriglyceridemia

Question 5

A patient with type II diabetes is prescribed a drug that enhances insulin sensitivity by activating AMP-activated protein kinase (AMPK). What is the primary effect of AMPK activation on lipid metabolism?

Accepted Answer

Inhibits fatty acid synthesis

Answer

Promotes fatty acid oxidation

Answer

Stimulates lipid synthesis

Answer

Increases fatty acid storage

Question 6

What is the primary cause of ketoacidosis in uncontrolled diabetes mellitus?

Accepted Answer

Fat metabolism producing ketone bodies

Answer

High blood glucose levels

Answer

Excessive insulin production

Answer

Lack of glucagon

Question 7

A patient with hypercholesterolemia has low LDL receptor activity. Which gene mutation is most likely responsible?

Accepted Answer

LDLR

Answer

APOB

Answer

PCSK9

Answer

APOE

Question 8

Which enzyme is responsible for converting dihydroxyacetone phosphate to glycerol-3-phosphate during triglyceride synthesis?

Accepted Answer

Glycerol-3-phosphate dehydrogenase

Answer

Glycerol kinase

Answer

Acyl-CoA synthetase

Answer

Phosphatidate phosphatase

Question 9

What is the role of lecithin-cholesterol acyltransferase (LCAT) in lipid metabolism?

Accepted Answer

Converts free cholesterol into cholesteryl esters

Answer

Hydrolyzes triglycerides in lipoproteins

Answer

Synthesizes triglycerides in the liver

Answer

Breaks down cholesterol into bile acids

Question 10

Which metabolic disorder is characterized by the accumulation of sphingomyelin in lysosomes?

Accepted Answer

Niemann-Pick disease

Answer

Tay-Sachs disease

Answer

Gaucher disease

Answer

Fabry disease

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?